The EGFR as a target for anticancer therapy--focus on cetuximab.

By J. Baselga. European Journal of Cancer, 2001

596 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/ca8cc007b26579ff2b1626966c0a312d8cf1de9e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. K. Imai
2. A. Takaoka

In Pulmonary and Respiratory Medicine

1. K. Imai
2. A. Takaoka

In Radiology, Nuclear Medicine and Imaging

1. K. Imai
2. A. Takaoka

Citations in the corpus

• Comparing antibody and small-molecule therapies for cancer (2006, background): “Cetuximab (also known as C225; Erbitux) is a chimeric IgG1-isotype mAb that binds to EGFR with high affinity and abrogates ligand-induced EGFR phosphorylatio”